Elephas Biosciences nets $40M to commercialize live profiling

Elephas Biosciences has closed a follow-on equity infusion of $40 million to accelerate commercialization and clinical testing of its functional tumour assay. The round, announced today, brings fresh capital to a platform designed to forecast which patients will respond to immunotherapies by testing live tissue ex vivo.

The equity round included participation from existing investors including Northpond Ventures, ARCH Venture Partners, the State of Wisconsin Investment Board, Tao Capital Partners, Sands Capital, Venture Investors Health Fund, among others.

Company executives said the proceeds will be channelled into expanded clinical validation, automation of the laboratory workflow and scaling of sample logistics to shorten the decision window for oncologists.

The investment arrives against a stark backdrop: cancer incidence is rising globally and the pace of innovation in immuno-oncology has outstripped the availability of accurate, actionable biomarkers. According to the company, only roughly one in five patients treated with immune checkpoint inhibitors experience objective benefit today — a gap that functional assays aim to narrow by directly measuring tumour and immune interactions rather than inferring biology from static genomic snapshots.

Elephas’ proprietary product, marketed as Elephas Live, preserves the native tumour microenvironment from a core needle biopsy and maintains cell–cell architecture during short-term culture. By profiling living tissue and sampling multiple regions to address intratumour heterogeneity, the platform yields dynamic readouts of immune activation and resistance mechanisms. That approach is positioned as complementary to DNA- or RNA-based diagnostics and could serve as a predictive tool to guide therapy selection or to enrich clinical trials.

With this round, Elephas Biosciences is positioning Elephas Live for the pivotal studies and operational scale-up needed to compete in an increasingly crowded precision-oncology diagnostics market. The fresh capital should help the company move from promising lab data toward the kind of clinical evidence that unlocks routine clinical adoption.